CF Foundation Invests $3M to Support Phage Therapy, AP-PA02

CF Foundation Invests $3M to Support Phage Therapy, AP-PA02

310787

CF Foundation Invests $3M to Support Phage Therapy, AP-PA02

The Cystic Fibrosis (CF) Foundation has invested $3 million in Armata Pharmaceuticals to support development of AP-PA02, a bacteriophage now being evaluated in a clinical trial for its ability to treat respiratory infections caused by Pseudomonas aeruginosa in people with cystic fibrosis (CF). “We are pleased by this investment by the CF Foundation as we endeavor to develop new, innovative therapies for difficult-to-treat bacterial infections for cystic fibrosis,” Brian Varnum, CEO of Armata, said in…

You must be logged in to read/download the full post.